


<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary) JUL 11 2003								ATTY. DOCKET NO. PC10607A		SERIAL NO. 09/814,442					
								APPLICANT SEAN EKINS, et al.		FILING DATE MARCH 22, 2001			GROUP 1631		
								<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIALS	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
	WAN	US	5	5	4	3	4	1	3	08/06/96	Townsend, et al.				
<b>RECEIVED</b> JUL 16 2003 <b>TECH CENTER 1600/2900</b>															
<b>FOREIGN PATENT DOCUMENTS</b>															
EXAMINER INITIALS	DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
	WAN	WO	9	2	1	2	1	3	7	07/23/92	PCT		YES	NO	
<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, Etc.)															
WAN		G.C. Moody, et al., Xenobiotica, (1999), Vol. 29, No. 1, pages 53-75													
WAN		G. A. McPherson, Journal of Pharmacological Methods, (1985), Vol 13, pages 125-134													
WAN		T. Kakkar, et al., Drug Metabolism and Disposition, (1999), Vol. 27, No. 6, pages 756-762													
EXAMINER				DATE CONSIDERED											
WAN				11/9/04											
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.															

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE




INFORMATION DISCLOSURE CITATION <small>TRADEMARKS Use several sheets if necessary)</small>			ATTY. DOCKET NO. PC10607A		SERIAL NO. 09/814,442				
			APPLICANT Sean Ekins						
1 or 4			FILING DATE 03/22/2001		GROUP 1614				
U.S. PATENT DOCUMENTS									
EXAMINER INITIAL	DOCUMENT NUMBER				DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS									
DOCUMENT NUMBER					DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
									YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)									
		Banks, M., et al., High throughput screening using fully integrated robotic screening. <i>J Biomolecular Screening</i> 2: 133-135, 1997							
		Bertz, R., et al., G. R.: Use of <i>in vitro</i> and <i>in vivo</i> data to estimate the likelihood of metabolic pharmacokinetic interactions. <i>Clin Pharmacokinet</i> 32: 210-258, 1997							
		Bronson, R., et al., Virtual kinetics: using statistical experimental design for rapid analysis of enzyme inhibitor mechanisms. <i>Biochem Pharmacol</i> 50: 822-831, 1995							
		Busby Jr, W., et al., Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on <i>in vitro</i> activities of cDNA-expressed human cytochromes P-450. <i>Drug Metab Dispos</i> 27: 246-249, 1999							
		Chauret, N., et al., Effect of common-organic solvents on <i>in vitro</i> cytochrome P450-mediated metabolic activities in human liver microsomes. <i>Drug Metab Dispos</i> 26: 14, 1998							
		Crespi, C., et al., Microtiter plate assays for inhibition of human drug-metabolizing cytochromes P450. <i>Anal Biochem</i> 248: 188-190, 1997							
		Crespi, C. et al., High throughput screening for inhibition of cytochrome P450 metabolism. <i>Med Chem Res</i> 8: 457-471, 1998							
		Cronin, M. T., et al., Computer-aided prediction of drug toxicity in high throughput screening. <i>Pharm Pharmacol Commun</i> 4: 157-163, 1998							
		Donato, M., et al., A microassay for measuring cytochrome P450IA1 and P450IB1 activities in intact human and rat hepatocytes cultured on 96-well plates. <i>Anal Biochem</i> 213: 29-33, 1993							
		Draper, A., et al., Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. <i>Arch Biochem Biophys</i> 341: 47-61, 1997							
		Ekins, S., et al., Three dimensional-quantitative structure activity relationship (3D-QSAR) analyses of inhibitors for CYP3A4. <i>J Pharmacol Exp Ther</i> 290: 429-438, 1999							
		Ekins, S., et al., Three dimensional-quantitative structure activity relationship (3D-QSAR) analyses of substrates for CYP2B6 <i>J Pharmacol Exp Ther</i> 288: 21-29, 1999b							
EXAMINER	DATE CONSIDERED								




INFORMATION DISCLOSURE

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>			ATTY. DOCKET NO. PC10607A		SERIAL NO. 09/814,442				
2 or 4			APPLICANT Sean Ekins						
			FILING DATE 03/22/2001		GROUP 1614				
<b>U.S. PATENT DOCUMENTS</b>									
EXAMINER INITIAL		DOCUMENT NUMBER			DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<b>FOREIGN PATENT DOCUMENTS</b>									
DOCUMENT NUMBER					DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
									YES NO
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>									
		Ekins, S., et al., Autoactivation and activation of cytochrome P450s. <i>Int J Clin Pharmacol Ther</i> 36: 642-651, 1998							
		FDA: Guidance for industry. Drug metabolism/drug interaction studies in the drug development process: studies in vitro. , 1997							
		FDA: Guidance for Industry. In vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling. , 1998							
		Fuhr, U., et al., Systematic screening for pharmacokinetic interactions during drug development. <i>Int J Clin Pharmacol Ther</i> 34: 139-151, 1996							
		Hickman, D., et al., Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. <i>Drug Metab Dispos</i> 26: 207-215, 1998							
		Hook, D.: Ultra high-throughput screening - a journey into nanoland with Gulliver and Alice. <i>Drug Discovery Today</i> 1: 267-268, 1996							
		Ito, K., et al., Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. <i>Pharmacol Rev</i> 50: 387-411, 1998							
		Korfmacher, W., et al., HPLC-API/MS/MS: a powerful tool for integrating drug metabolism into the drug discovery process. <i>Drug Discovery Today</i> 12: 532-537, 1997							
		Kronbach, T., et al. High performance liquid chromatography assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. <i>Anal Biochem</i> 162: 24-32, 1987							
		Leeman, T., et al., Cytochrome P450TB (CYP2C): A major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. <i>Life Sci</i> 52: 29-34, 1992							
		Lin, J., et al., Inhibition of cytochrome P-450 and implications in drug development. <i>Ann Rep Med Chem</i> 32: 295-304, 1997							
EXAMINER			DATE CONSIDERED						
<p style="text-align: right;">MAY 11 2004</p>									



INFORMATION DISCLOSURE CITATION <small>(Use several sheets if necessary)</small>			ATTY. DOCKET NO. PC10607A			SERIAL NO. 09/814,442				
			APPLICANT Sean Ekins			FILING DATE 03/22/2001			GROUP 1614	
3 of 4										
<b>U.S. PATENT DOCUMENTS</b>										
EXAMINER INITIAL		DOCUMENT NUMBER				DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<b>FOREIGN PATENT DOCUMENTS</b>										
DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
										YES NO
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>										
		Lin, J., et al., Inhibition and induction of cytochrome P450 and the clinical implications. <i>Clin Pharmacokinet</i> 35: 361-390, 1998								
		Lutz, M., et al., Experimental design for high-throughput screening. <i>Drug Discovery Today</i> 1: 277-286, 1996								
		Maenpaa, P., et al., Human cytochrome P4503A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by a-naphthoflavone, terfenadine and testosterone. <i>Pharmacogenetics</i> 8, 1998								
		Miwa, G. T., et al., Goals, design, timing, and future opportunities for non clinical drug metabolism studies. <i>Toxicol Pathol</i> 23: 131-135, 1995								
		Pichard, L., et al., Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. <i>Drug Metab Dispos</i> 18: 595-606, 1990								
		Rodrigues, A., et al., Preclinical drug metabolism in the age of high-throughput screening: An industrial perspective. <i>Pharm Res</i> 14: 1504-1510, 1997								
		Rodrigues, A., et al., [O-ethyl 14C] phenacetin O-deethylase activity in human liver microsomes. <i>Drug Metab Dispos</i> 25: 1097-1100, 1997								
		Shimada, T., et al., Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. <i>J Pharmacol Exp Pharmacol</i> 270: 414-423, 1994								
		Singh, J., et al., Lead development: validation and application of high throughput screening for determination of pharmacokinetic parameters for enzyme inhibitors. <i>Bioorg Med Chem</i> 4: 639-643, 1996								
		Sittampalam, G., et al., Design of signal windows in high throughput screening assays for drug discovery. <i>J Biomolecular Screening</i> 2: 159-169, 1997								
		Smith, D., et al., Human cytochrome P450s: selectivity and measurement in vivo. <i>Xenobiotica</i> 28: 1095-1128, 1998								
EXAMINER			DATE CONSIDERED							

INFORMATION DISCLOSURE CITATION	ATTY. DOCKET NO. PC10607A	SERIAL NO. 09/814,442
---------------------------------	---------------------------	-----------------------



(Use several sheets if necessary)

4 of 4

APPLICANT Sean Ekins

FILING DATE 03/22/2001

GROUP 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Sonderfan, A., et al., Regulation of testosterone hydroxylation by rat liver microsomal cytochrome-P450. <i>Arch Biochem Biophys</i> 255: 27-41, 1987.
		Spencer, R., High-throughput screening of historic collections: observations on file size, biological targets and file diversity. <i>Biotechnol Bioeng</i> 61: 61-67, 1998
		Tarbit, M., et al., High-throughput approaches for evaluating absorption, distribution, metabolism and excretion properties of lead compounds. <i>Curr Opin Chem Biol</i> 2: 411-416, 1998
		Tucker, G., et al., The rational selection of drug interaction studies: implications of recent advances in drug metabolism. <i>Int J Clin Pharmacol Ther</i> 30: 550-553, 1992
		van der Hoeven, T., et al., Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P450-reductase from rabbit liver microsomes. <i>J Biol Chem</i> 249: 6302-6310, 1974
		van der Voet, H.: Comparing the predictive accuracy of models using a simple randomization test. <i>Chem Int Lab Systems</i> 25: 313-323, 1994
		Wrighton, S., et al., The use of in vitro metabolism techniques in the planning and interpretation of drug safety studies. <i>Toxicologic Pathology</i> 23 (2): 199-208, 1995
		Wrighton, S., et al., In vitro methods for assessing human hepatic drug metabolism: their use in drug development. <i>Drug Metab Rev</i> 25 (4): 453-84, 1993
		Wynalda, M., et al., Assessment of potential interactions between dopamine agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. <i>Drug Metab Dispos</i> 25: 1211-1214, 1997

EXAMINER

DATE CONSIDERED